FDA has accepted an Interim Analysis Plan for an IDMC to assess clinical outcome when 36 patients are enrolled in the Company s Ph2b clinical trial of.
Acurx Pharmaceuticals (ACXP) Announces FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of.
The hunt for new and potentially potent therapeutic molecules in nature is a vital quest spurred on by parallel health crises: antibacterial resistance and the growing global cancer burden.